FY2024 EPS Estimates for AxoGen Lowered by Cantor Fitzgerald

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2024 earnings per share (EPS) estimates for AxoGen in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now anticipates that the medical equipment provider will post earnings per share of ($0.58) for the year, down from their previous estimate of ($0.28). The consensus estimate for AxoGen's current full-year earnings is ($0.30) per share. Cantor Fitzgerald also issued estimates for AxoGen's FY2025 earnings at $0.19 EPS.

Separately, StockNews.com upgraded shares of AxoGen from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th.

AxoGen Stock Down 1.0 %

NASDAQ AXGN traded down $0.19 during trading hours on Thursday, hitting $18.71. 362,895 shares of the company were exchanged, compared to its average volume of 650,931. The company has a 50 day moving average of $15.40 and a two-hundred day moving average of $13.30. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The firm has a market cap of $823.21 million, a price-to-earnings ratio of -58.60 and a beta of 1.01. AxoGen has a 52-week low of $5.55 and a 52-week high of $19.06.

Institutional Trading of AxoGen

A number of institutional investors have recently bought and sold shares of AXGN. Quest Partners LLC lifted its stake in AxoGen by 23,066.7% during the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 2,076 shares during the last quarter. R Squared Ltd acquired a new stake in AxoGen during the fourth quarter worth approximately $30,000. nVerses Capital LLC purchased a new stake in shares of AxoGen during the 3rd quarter worth approximately $56,000. Oppenheimer & Co. Inc. acquired a new position in shares of AxoGen in the 3rd quarter valued at $156,000. Finally, Quantbot Technologies LP purchased a new position in shares of AxoGen in the 3rd quarter valued at $165,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.